Dendritic cells (DCs) contribute a small fraction of the tumor microenvironment but are emerging as an essential antitumor component based on their ability to foster T cell immunity and immunotherapy responses. Here, we discuss our expanding view of DC heterogeneity in human tumors, as revealed with meta-analysis of single-cell transcriptome profiling studies. We further examine tumor-infiltrating DC states that are conserved across patients, cancer types, and species and consider the fundamental and clinical relevance of these findings. Finally, we provide an outlook on research opportunities to further explore mechanisms governing tumor-infiltrating DC behavior and functions.
Tumor-infiltrating dendritic cell states are conserved across solid human cancers
Disclosures: R. Bill reported that is wife is an employee and stockholder of CSL Behring. His salary is funded by a postdoc fellowship of the Swiss National Science Foundation (SNSF; P400PM_183852). M.J. Pittet reported personal fees from Aileron Therapeutics, AstraZeneca, Cygnal Therapeutics, Elstar Therapeutics, KSQ Therapeutics, Merck, and Siamab Therapeutics outside the submitted work. No other disclosures were reported.
- Views Icon Views
- Share Icon Share
- Search Site
Genevieve M. Gerhard, Ruben Bill, Marius Messemaker, Allon M. Klein, Mikael J. Pittet; Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J Exp Med 4 January 2021; 218 (1): e20200264. doi: https://doi.org/10.1084/jem.20200264
Download citation file: